EUCTR2021-001202-30-NLActive, not recruitingPhase 1
SARS-CoV-2 immune response
Diakonessenhuis0 sites400 target enrollmentStarted: April 16, 2021Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Before and after COVID-19 vaccination
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
Exclusion Criteria
- •< 18 years old
Investigators
Similar Trials
Recruiting
Not Applicable
SARS-CoV-2 immune responseCOVID-1910047438NL-OMON55057Diakonessenhuis Utrecht800
Completed
Not Applicable
Immune response against SARS-CoV-2 vaccinatioCOVID-19DRKS00028174DKFZ6
Not yet recruiting
Not Applicable
Response rate to SARS-CoV-2 (COVID-19) vaccine in dialysis patients.JPRN-UMIN000043368agasaki University110
Completed
Not Applicable
Immune response to COVID-19 vaccination in patients with autoimmune disorders on various types of immunosuppressive treatmentsImmune response to COVID-19 (SARS-CoV-2 infection) vaccination in patients on immunosuppressive therapyInfections and InfestationsISRCTN68832164Charles University199
Recruiting
Phase 4
Efficacy of vaccine responses against SARS-Cov-2 in patients with giant cell arteritis and polymyalgia rheumatica (GPSVAC)NL-OMON51139niversitair Medisch Centrum Groningen80